Merck outflanks Pfizer's 20-valent shot with pneumococcal vaccine approval for kids
Back in April, the FDA asked for more analysis from Merck on its 15-valent pneumococcal vaccine for children and pushed back its approval deadline by three months. As the three-month mark approaches, the FDA appears to be satisfied.
Merck announced today that the FDA approved its vaccine for children ages 6 weeks and up, making it the third pneumococcal shot approved for children. The vaccine, which is marketed as Vaxneuvance, was already OK’d for adults back in July 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.